ID24929A - Turunan 2-aril-8-oksodihidropurin, proses pembuatannya, komposisi farmasinya yang mengandungnya, dan senyawa antaranya - Google Patents

Turunan 2-aril-8-oksodihidropurin, proses pembuatannya, komposisi farmasinya yang mengandungnya, dan senyawa antaranya

Info

Publication number
ID24929A
ID24929A IDW20000990A ID20000990A ID24929A ID 24929 A ID24929 A ID 24929A ID W20000990 A IDW20000990 A ID W20000990A ID 20000990 A ID20000990 A ID 20000990A ID 24929 A ID24929 A ID 24929A
Authority
ID
Indonesia
Prior art keywords
oxyodihydrropurin
durunan
aril
pharmacy
compound
Prior art date
Application number
IDW20000990A
Other languages
English (en)
Indonesian (id)
Inventor
Teruya Murata
Kaoru Masumoto
Katsunori Kondo
Kiyoshi Furukawa
Makoto Oka
Original Assignee
Dainippon Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dainippon Pharmaceutical Co filed Critical Dainippon Pharmaceutical Co
Publication of ID24929A publication Critical patent/ID24929A/id

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IDW20000990A 1997-12-03 1998-11-26 Turunan 2-aril-8-oksodihidropurin, proses pembuatannya, komposisi farmasinya yang mengandungnya, dan senyawa antaranya ID24929A (id)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP35000097 1997-12-03

Publications (1)

Publication Number Publication Date
ID24929A true ID24929A (id) 2000-08-31

Family

ID=18407561

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW20000990A ID24929A (id) 1997-12-03 1998-11-26 Turunan 2-aril-8-oksodihidropurin, proses pembuatannya, komposisi farmasinya yang mengandungnya, dan senyawa antaranya

Country Status (26)

Country Link
US (1) US6372740B1 (de)
EP (1) EP1036794B1 (de)
JP (1) JP3815966B2 (de)
KR (1) KR100494347B1 (de)
CN (1) CN1146566C (de)
AR (1) AR017796A1 (de)
AT (1) ATE248169T1 (de)
AU (1) AU744014B2 (de)
BR (1) BR9815140A (de)
CA (1) CA2312885C (de)
DE (1) DE69817611T2 (de)
DK (1) DK1036794T3 (de)
ES (1) ES2205574T3 (de)
HU (1) HUP0004422A3 (de)
ID (1) ID24929A (de)
IL (1) IL135920A0 (de)
NO (1) NO20002835L (de)
NZ (1) NZ504457A (de)
PL (1) PL191489B1 (de)
PT (1) PT1036794E (de)
RU (1) RU2223272C2 (de)
SK (1) SK285703B6 (de)
TR (1) TR200001600T2 (de)
TW (1) TW502034B (de)
WO (1) WO1999028320A1 (de)
ZA (1) ZA9810490B (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003146987A (ja) * 1999-05-31 2003-05-21 Dainippon Pharmaceut Co Ltd ２−アリールプリン−９−アセトアミド誘導体
GB9913932D0 (en) * 1999-06-15 1999-08-18 Pfizer Ltd Purine derivatives
HUP0203835A3 (en) * 1999-09-27 2003-07-28 Ono Pharmaceutical Co Pyrimidine derivatives, process for preparing the derivatives and drugs containing the same as the active ingredient
KR100829297B1 (ko) * 2000-07-31 2008-05-13 다이닛본 스미토모 세이야꾸 가부시끼가이샤 2-아릴-8-옥소디히드로푸린 유도체를 유효성분으로 하는치매증 치료제
AR045445A1 (es) * 2003-08-05 2005-10-26 Vertex Pharma Compuestos ihinibidores de canales ionicos regulados por voltaje
JPWO2005080334A1 (ja) * 2004-02-23 2007-08-02 大日本住友製薬株式会社 新規ヘテロ環化合物
EP1734820A4 (de) * 2004-04-16 2008-01-23 Neurogen Corp Imidazopyrazine, imidazopyridine und imidazopyrimidine als crf1-rezeptorliganden
FR2870239B1 (fr) * 2004-05-11 2006-06-16 Sanofi Synthelabo Derives de carbamate de 2h- ou 3h-benzo[e]indazol-1-yle, leur preparation et leur application en therapeutique.
US7884109B2 (en) * 2005-04-05 2011-02-08 Wyeth Llc Purine and imidazopyridine derivatives for immunosuppression
KR20080013886A (ko) * 2005-04-05 2008-02-13 파마코페이아, 인코포레이티드 면역억제용 퓨린 및 이미다조피리딘 유도체
GB0507298D0 (en) 2005-04-11 2005-05-18 Novartis Ag Organic compounds
US20070225304A1 (en) * 2005-09-06 2007-09-27 Pharmacopeia Drug Discovery, Inc. Aminopurine derivatives for treating neurodegenerative diseases
US20090281075A1 (en) * 2006-02-17 2009-11-12 Pharmacopeia, Inc. Isomeric purinones and 1h-imidazopyridinones as pkc-theta inhibitors
US7989459B2 (en) * 2006-02-17 2011-08-02 Pharmacopeia, Llc Purinones and 1H-imidazopyridinones as PKC-theta inhibitors
CN101454325A (zh) * 2006-03-09 2009-06-10 法马科皮亚公司 用于治疗代谢性疾病的8-杂芳基嘌呤mnk2抑制剂
US7902187B2 (en) * 2006-10-04 2011-03-08 Wyeth Llc 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
AR063141A1 (es) * 2006-10-04 2008-12-30 Pharmacopeia Inc Derivados de 2- ( benzimidazolil ) purina 8- sustituida para inmunosupresion
TW200831104A (en) * 2006-10-04 2008-08-01 Pharmacopeia Inc 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
NZ576278A (en) 2006-10-19 2011-12-22 Signal Pharm Llc Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors
US20080119496A1 (en) * 2006-11-16 2008-05-22 Pharmacopeia Drug Discovery, Inc. 7-Substituted Purine Derivatives for Immunosuppression
JP2009007273A (ja) 2007-06-27 2009-01-15 Ajinomoto Co Inc ジアミノピリミジン化合物の製造方法
US8110578B2 (en) 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
US8473571B2 (en) 2009-01-08 2013-06-25 Microsoft Corporation Synchronizing presentation states between multiple applications
ES2626246T3 (es) * 2009-09-09 2017-07-24 Sumitomo Dainippon Pharma Co., Ltd. Derivado de 8-oxodihidropurina
KR20120091240A (ko) 2009-10-26 2012-08-17 시그날 파마소티칼 엘엘씨 헤테로아릴 화합물의 합성 및 정제 방법
JP2014076947A (ja) * 2011-02-03 2014-05-01 Dainippon Sumitomo Pharma Co Ltd ２−オキシ置換８−オキソジヒドロプリン誘導体
US20140301947A1 (en) 2011-06-06 2014-10-09 Imperial Innovations Limited Methods to predict binding affinity of tspo imaging agents to tspo
EP3466423B1 (de) 2011-10-19 2021-07-28 Signal Pharmaceuticals, LLC Behandlung von krebs mit tor-kinasehemmern
BR112014013332B1 (pt) 2011-12-02 2022-09-06 Signal Pharmaceuticals, Llc Composições farmacêuticas de 7-(6-(2-hidroxi-propan-2-il)piridin-3-il)-1-((trans)-4- metoxicicloexil)-3,4-diidropirazino [2,3-b]pirazin-2(1h)-ona, uma forma sólida dessa e métodos de seu uso
KR102064626B1 (ko) 2012-02-24 2020-01-09 시그날 파마소티칼 엘엘씨 Tor 키나제 억제자 복합 치료법을 사용한 비소세포 폐암의 치료 방법
CN102675315B (zh) * 2012-02-28 2015-04-01 中国人民解放军第四军医大学 含取代苯烷基的嘌呤类化合物和制备方法及应用
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
US9346812B2 (en) 2013-01-16 2016-05-24 Signal Pharmaceuticals, Llc Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
HK1221150A1 (zh) 2013-04-17 2017-05-26 西格诺药品有限公司 用二氢吡嗪并-吡嗪类对癌症的治疗
CN105339008A (zh) 2013-04-17 2016-02-17 西格诺药品有限公司 用于治疗癌症的包括tor激酶抑制剂和n-(3-(5-氟-2-(4-(2-甲氧基乙氧基)苯基氨基)嘧啶-4-基氨基)苯基)丙烯酰胺的组合疗法
EP2986321A1 (de) 2013-04-17 2016-02-24 Signal Pharmaceuticals, LLC Kombinationstherapie mit einem torkinaseinhibitor und einem cytidinanalogon zur behandlung von krebs
MX368286B (es) 2013-04-17 2019-09-27 Signal Pharm Llc Terapia de combinacion que comprende un inhibidor de tor cinasa y un compuesto de quinazolinona 5-sustituida para tratar cancer.
BR112015026257B1 (pt) 2013-04-17 2022-12-20 Signal Pharmaceuticals, Llc Uso de um composto dihidropirazino-pirazina e enzalutamida, composição farmacêutica que os compreende, e kit
JP6382945B2 (ja) 2013-04-17 2018-08-29 シグナル ファーマシューティカルズ，エルエルシー ジヒドロピラジノ−ピラジンによる癌治療
MX393164B (es) 2013-04-17 2025-03-21 Signal Pharm Llc Formulaciones farmacéuticas, proceso, formas sólidas y métodos de uso relacionados con 1-etil-7-(2-metil-6-(1h-1,2,4-triazol-3-ii)piridin-3-ii)-3,4-dihidropirazino[2,3-b]pirazin-2(1h)-ona.
NZ629486A (en) 2013-05-29 2017-11-24 Signal Pharm Llc Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use
US9718824B2 (en) 2014-04-16 2017-08-01 Signal Pharmaceuticals, Llc Solid forms comprising 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one, and a coformer, compositions and methods of use thereof
EP3131551A4 (de) 2014-04-16 2017-09-20 Signal Pharmaceuticals, LLC Feste formen mit 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-on und co-former, zusammensetzungen und verfahren zu deren verwendung
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
WO2015160868A1 (en) 2014-04-16 2015-10-22 Signal Pharmaceuticals, Llc Methods for treating cancer using tor kinase inhibitor combination therapy
NZ629796A (en) 2014-07-14 2015-12-24 Signal Pharm Llc Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
AU2015289929A1 (en) 2014-07-14 2017-03-02 Signal Pharmaceuticals, Llc Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof
RU2750151C2 (ru) 2015-11-20 2021-06-22 Форма Терапьютикс, Инк. Гипоксантины в качестве ингибиторов убиквитин-специфической протеазы 1
IL271491B2 (en) 2017-06-22 2023-09-01 Celgene Corp Treatment of carcinoma of the liver characterized by hepatitis b virus infection
EP3752505B1 (de) 2018-02-12 2023-01-11 F. Hoffmann-La Roche AG Neuartige sulfonverbindungen und derivate zur behandlung und prophylaxe einer virusinfektion

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2525595A1 (fr) 1982-04-27 1983-10-28 Pharmuka Lab Nouveaux derives d'arene et d'heteroarenecarboxamides et leur utilisation comme medicaments
NL8202626A (nl) * 1982-06-29 1984-01-16 Stichting Rega V Z W Derivaten van 9-(2-hydroxyethoxymethyl)guanine.
FR2582514B1 (fr) 1985-05-30 1988-02-19 Rhone Poulenc Sante Medicaments a base d'amides, nouveaux amides et leur preparation
DK273689A (da) 1988-06-06 1989-12-07 Sanofi Sa 4-amino-3-carboxyquinoliner og -naphthyridiner, fremgangsmaade til deres fremstilling og anvendelse deraf i laegemidler
FR2632639B1 (fr) * 1988-06-09 1990-10-05 Sanofi Sa Derives d'amino-4 carboxy-3 naphtyridines, leur preparation et compositions pharmaceutiques qui les contiennent
US5840891A (en) 1994-07-28 1998-11-24 Syntex (U.S.A.) Inc. 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl) methoxy-1,3-propanediol derivative
IL117659A (en) 1995-04-13 2000-12-06 Dainippon Pharmaceutical Co Substituted 2-phenyl pyrimidino amino acetamide derivative process for preparing the same and a pharmaceutical composition containing same
KR19990044383A (ko) 1996-07-03 1999-06-25 나가시마 카쭈시게, 노미야마 아키히코 신규 퓨린 유도체
JP2002501493A (ja) * 1997-04-22 2002-01-15 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｃｒｆアンタゴニストのチオフェノピリジン類
JP3814125B2 (ja) * 1999-06-02 2006-08-23 大日本住友製薬株式会社 ２−アリール−８−オキソジヒドロプリン誘導体からなる医薬

Also Published As

Publication number Publication date
HUP0004422A3 (en) 2001-10-29
IL135920A0 (en) 2001-05-20
SK7972000A3 (en) 2001-03-12
TR200001600T2 (tr) 2000-11-21
TW502034B (en) 2002-09-11
EP1036794B1 (de) 2003-08-27
CN1284076A (zh) 2001-02-14
KR20010032686A (ko) 2001-04-25
US6372740B1 (en) 2002-04-16
NO20002835L (no) 2000-07-24
CA2312885A1 (en) 1999-06-10
ES2205574T3 (es) 2004-05-01
DE69817611T2 (de) 2004-02-26
EP1036794A1 (de) 2000-09-20
NO20002835D0 (no) 2000-06-02
CA2312885C (en) 2008-01-29
PL340925A1 (en) 2001-03-12
DE69817611D1 (de) 2003-10-02
PT1036794E (pt) 2003-11-28
CN1146566C (zh) 2004-04-21
AU744014B2 (en) 2002-02-14
KR100494347B1 (ko) 2005-06-13
BR9815140A (pt) 2000-10-10
PL191489B1 (pl) 2006-05-31
ZA9810490B (en) 1999-05-20
AU1260499A (en) 1999-06-16
SK285703B6 (sk) 2007-06-07
ATE248169T1 (de) 2003-09-15
DK1036794T3 (da) 2003-12-22
NZ504457A (en) 2001-12-21
RU2223272C2 (ru) 2004-02-10
HK1028769A1 (en) 2001-03-02
EP1036794A4 (de) 2001-12-12
AR017796A1 (es) 2001-10-24
WO1999028320A1 (en) 1999-06-10
HUP0004422A2 (hu) 2001-04-28
JP3815966B2 (ja) 2006-08-30

Similar Documents

Publication Publication Date Title
ID24929A (id) Turunan 2-aril-8-oksodihidropurin, proses pembuatannya, komposisi farmasinya yang mengandungnya, dan senyawa antaranya
ID30299A (id) Turunan oksazolidinon, proses pembuatannya dan komposisi farmasi yang mengandungnya
ID25528A (id) Karboksamidotiazol tersubstitusi, pembuatannya dan komposisi farmasi yang mengandungnya
ID17307A (id) Komposisi oral dan proses pembuatannya.
ID16128A (id) Turunan arilglisinamida baru, proses pembuatannya dan komposisi-komposisi farmasi yang mengandung senyawa ini
ID26399A (id) Turunan 1-(1-tersubstitusi-4-piperidinil) metil -4-piperidin, proses pembuatannya, komposisi farmasi yang mengandung senyawa tersebut, dan intermedietnya
ID18046A (id) Senyawa siklik campuran, pembuatan dan penngunaannya.
ID26589A (id) 4-haloalkil -3-heterosiklilpiridina dan 4- haloalkil-5-heterosiklilpirimidina proses untuk pembuatannya komposisi yang terdiri darinya dan pemakaiannya sebagai pestisida
ID21045A (id) Asam amino termodifikasi, obat-obatan yang mengandung senyawa ini dan proses pembuatannya
ID28728A (id) Komposisi dan proses pengkrepan
ID15947A (id) Senyawa fenol dan proses pembuatannya
ID22528A (id) Komposisi farmasi fenofibrat yang memiliki biovabilitas tinggi dan metoda pembuatannya
ID22821A (id) Turunan sulfonamida, proses pembuatannya dan penggunaannya sebagai obat
ID19290A (id) Turunan-turunan propiofenon dan proses pembuatannya
ID26172A (id) Proses pembuatan surfaktan-surfaktan alkilbenzenasulfonat dan produk-produknya
ID27680A (id) Komposisi poliester, metoda produksi daripadanya dan film poliester
ID29236A (id) Benzopiran-benzopiran dan benzoksepin-benzoksepin, komposisi-komposisi famaseutikal yang mengandungnya, dan proses penyiapannya
ID20604A (id) Polisakarida sintetis proses untuk pembuatan dan komposisi farmasi yang dikandungnya
ID25469A (id) Komposisi sefalosporin amorf yang stabil secara kristalografi dan proses pembuatannya
ID20137A (id) Turunan propanolamina, proses pembuatannya, sediaan farmasi yang mengandung senyawa ini, dan penggunannya
ID17810A (id) Turunan-turunan 2,4-tiazolidindion tersubstitusi baru, proses untuk pembuatannya dan komposisi farmasi yang mengandungnya
ID29295A (id) Senyawa pirimidinona, komposisi farmasi yang mengandung senyawa tersebut dan proses penyediaannya senyawa tersebut
ID23436A (id) Senyawa-senyawa akrilonitril, proses untuk produksinya dan pestisida-pestisida yang mengandungnya
ID22911A (id) Turunan-turunan triazol baru, proses pembuatan dan komposisi-komposisi farmasi yang mengandungnya
ID24714A (id) Turunan tiazolidindion tersubstitusi, proses pembuatannya dan penggunaan bahan farmasinya